Opened 214 days ago
Closes 25 July 2025
Trial Aim Description
We’re investigating how genetically-guided treatment compares with the traditional treatments for youth depression and anxiety.
In this study, we aim to assess the effectiveness of antidepressant treatments by comparing changes in depression symptoms and side effects between two groups of participants. One group will receive medications selected based on pharmacogenetic (PGx) test results, while the other will be treated with standard antidepressants according to current clinical guidelines. Should PGx testing prove beneficial, it could result in faster and more significant improvements in depression symptoms.
Inclusion Criteria
- Participants are aged between 16 to 24 years (inclusive).
- Participants are confident in written and spoken English (to the level of being able to understand the Participant Information and Consent Form and engage with research staff).
- Planning to start antidepressant therapy, or wanting to change medication.
Principal Investigator: Jenny Rodger
Trial Coordinator: Zahra Cooper
Link to register interest: https://redcap.link/gene-yd-eoi-form
Enquiries Email: pgx@perron.uwa.edu.au